Cargando…
Quantification of Plasma Cell-Free DNA(1) in Predicting Therapeutic Efficacy of Sorafenib on Metastatic Clear Cell Renal Cell Carcinoma
PURPOSE: The objective of this study is to determine whether or not plasma cfDNA levels can predict efficacy of sorafenib in patient with metastatic cRCC. MATERIALS AND METHODS: Plasma cfDNA levels were quantified by quantitative real-time PCR at six different time-points (before treatment, 4 weeks,...
Autores principales: | Feng, Gang, Ye, Xiaobing, Fang, Fang, Pu, Chun, Huang, Houbao, Li, Guorong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3810240/ https://www.ncbi.nlm.nih.gov/pubmed/23324577 http://dx.doi.org/10.3233/DMA-120950 |
Ejemplares similares
-
Sorafenib in the management of metastatic renal cell carcinoma
por: Guevremont, C., et al.
Publicado: (2009) -
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
por: Procopio, G, et al.
Publicado: (2011) -
Determining Front-Line Therapeutic Strategy for Metastatic Clear Cell Renal Cell Carcinoma
por: Zarrabi, Kevin K., et al.
Publicado: (2022) -
Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma
por: Xu, Kevin Y, et al.
Publicado: (2015) -
Heme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib
por: Zheng, Wan-Xiang, et al.
Publicado: (2015)